文献速递胸部肿瘤放疗姑息放疗与转移瘤

低剂量放疗联合同步阿替利珠单抗及化疗一线治疗广泛期小细胞肺癌:多中心单臂2期试验MATCH的3年随访

Low-dose Radiation Therapy Concurrent With Atezolizumab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: 3-Year Follow-up of a Multicenter, Single-arm, Phase 2 Trial (MATCH).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-07-01

中位随访36.1个月,确认客观缓解率87.5%,中位无进展生存期6.9个月,中位总生存期16.9个月,3年总生存率35.1%,安全性可耐受。

要点

  • 确认客观缓解率达87.5%(95%CI 75.9-94.8),中位PFS 6.9个月,中位OS 16.9个月。
  • 3年OS率35.1%,肿瘤缓解深度高于中位者3年OS率57.4%,低于中位者18.8%。
  • 最常见3-5级治疗相关不良事件为中性粒细胞计数下降(60.7%)和白细胞计数下降(58.9%)。

核心结论

  • 初治低剂量放疗同步阿替利珠单抗联合化疗作为广泛期小细胞肺癌一线治疗有效且可耐受,需随机对照试验进一步验证。

研究设计与样本

  • 患者接受4个21天周期顺铂(75 mg/m2)或卡铂(AUC 5 mg/mL/min)、依托泊苷(100 mg/m2)和阿替利珠单抗(1200 mg)静脉给药,同步低剂量放疗(15 Gy分5次,3 Gy/次),后阿替利珠单抗维持治疗。
  • 主要终点为确认客观缓解率,次要终点为无进展生存期和总生存期。

主要发现

  • 确认客观缓解率为87.5%(95% CI,75.9-94.8)。
  • 中位无进展生存期为6.9个月(95% CI,5.4-9.3),中位总生存期为16.9个月(95% CI,14.0-32.9)。
  • 1年和3年无进展生存率分别为27.3%和20.7%,1年和3年总生存率分别为69.6%和35.1%。
  • 确认客观缓解患者的中位肿瘤缓解深度为70.2%;缓解深度高于和低于中位者3年总生存率分别为57.4%和18.8%(风险比0.28;95% CI,0.13-0.60)。
  • 最常见3-5级治疗相关不良事件为中性粒细胞计数下降(60.7%)和白细胞计数下降(58.9%)。

临床怎么用

  • 对于初治广泛期小细胞肺癌,可考虑低剂量放疗同步阿替利珠单抗联合铂类/依托泊苷化疗作为一线治疗选择,但需在随机对照试验验证前谨慎评估。
  • 治疗期间需密切监测中性粒细胞和白细胞计数下降等血液学毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Preclinical studies showed that low-dose radiation therapy (LDRT) may act synergistically with immunotherapy in small cell lung cancer (SCLC); however, its role in the treatment of extensive-stage SCLC (ES-SCLC) remains unclear. METHODS AND MATERIALS: This single-arm, multicenter, Simon's 2-stage, phase 2 study enrolled treatment-naïve patients with ES-SCLC. Patients received 4 21-day cycles of intravenous cisplatin (75 mg/m2) or carboplatin (area under the curve value, 5 mg/mL/min), etoposide (100 mg/m2), and atezolizumab (1200 mg), with concurrent LDRT (15 Gy in 5 fractions [3 Gy/fraction]), followed by atezolizumab maintenance therapy until loss of clinical benefit, unacceptable toxicity, withdrawal of consent, or death. The primary endpoint was the confirmed objective response rate. The secondary endpoints were progression-free survival (PFS) and overall survival (OS). RESULTS: Fifty-six eligible patients were enrolled between December 16, 2020, and March 30, 2022. The median follow-up was 36.1 months (IQR, 30.9-38.7) at the cutoff date (June 30, 2024). The confirmed objective response rate was 87.5% (95% CI, 75.9-94.8). The median PFS and OS were 6.9 months (95% CI, 5.4-9.3) and 16.9 months (95% CI, 14.0-32.9), respectively. The PFS rates at 1 and 3 years were 27.3% and 20.7%, respectively, and the OS rates at 1 and 3 years were 69.6% and 35.1%. The median depth of tumor response among patients with confirmed objective response was 70.2%. The 3-year OS rates were 57.4% and 18.8% in patients above and below the median depth of tumor response, respectively (hazard ratio, 0.28; 95% CI, 0.13-0.60). The most common treatment-related grades 3 to 5 adverse events were decreased neutrophil count (60.7%) and decreased white blood cell count (58.9%). CONCLUSIONS: These findings suggest that upfront LDRT concurrent with atezolizumab plus chemotherapy was effective and tolerable as first-line treatment for ES-SCLC, warranting further verification in randomized controlled trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhou L, Sun J, Xie C, et al. Low-dose Radiation Therapy Concurrent With Atezolizumab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: 3-Year Follow-up of a Multicenter, Single-arm, Phase 2 Trial (MATCH). Int J Radiat Oncol Biol Phys. 2025. PMID: 40609842. doi:10.1016/j.ijrobp.2025.06.3872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。